1907 - The Company was Incorporated at Vadodara. The Company
manufacture chemicals, pharmaceuticals, injections,
antibiotics, sulphuric acid, superphosphate and other
fertilisers, generating electricity, manufacture of
items, running of hospitals and health care units, etc.
1938 - The authorised capital was Rs 20 lakhs divided into 10,000-6
preference shares of Rs 100 each and 10,000 No. of equity
of Rs 100 each. 5,000 preference shares and all equity
were issued and subscribed.
1942 - 5,000-6% preference shares were issued and subscribed.
1944 - The authorised capital was increased to Rs 50 lakhs by the
creation of 30,000 shares of Rs 100 each out of which 3,000
shares were classified as equity shares and issued to the
shareholders in the proportion 3:10.
1946 - The Company issued 2,000 No. of equity shares as rights at a
premium of Rs 150 per share in the proportion 2:13.
1947 - 5,000 unclassified shares were converted into equity, shares
they were issued as rights at a premium of Rs 150 per share
the proportion 1:3.
1948 - 5,000 unclassified shares were converted into equity shares
issued as bonus in the proportion 1:4.
1949 - The authorised capital was increased to Rs 1 crore by creation
5,000-6% third preference shares of Rs 100 each and 45,000
unclassified shares of Rs 100 each. Further 7,000
shares were converted into equity shares and issued as bonus
the proportion of 2:3 irrespective of class.
1958 - The authorised, issued and paid-up capital stood at Rs
and Rs 80,00,000 respectively as at 31st December.
1959 - 20,000 Right Equity shares offered at par in prop. 1:4 to all
classes. In 1961, 10,000 Right Equity shares offered at par
prop. 1:1 to classes.
1962 - 9,500 Bonus equity shares issued in prop; 1:10, 40,000 Right
Equity shares offered at a prem. of Rs 30 per share in the
4:11 irrespective of class.
1966 - In Dec. 48,167 Bonus Equity shares issued in prop. 1:3.
No. of equity shares issued without payment in cash to
of Alembic Distributors Ltd., Mumbai and Alembic distributing
Agency, Bangalore on their merger.
1967 - The amalgamation on Alembic Distributors, Ltd., with the
from 1st January, was sanctioned by the High Courts of
and Mumbai. The Scheme of Amalgamation of Neomer Ltd. with
Company from the appointed date 1.1.1983 was approved by the
Court of Gujarat by its Order dated 12.9.1986.
1968 - 25,080 Right Equity shares issued at par in prop. 5:41.
- In March 1971, 57,487 Right Equity shares issued at par in
1977 - 6 1/4% Pref. and 6% III Pref. shares converted to 9%
Pref. shares from 1.1.1976. 5,000-5% Pref. shares redeemed
Rs 105 per shares on 1.1.1977.
1979 - The Company issued 75,000 secured debentures of Rs 100 each
rights to augment the resources of working capital.
1980 - Redeemed 1,000 Pref. shares each on 1.1.1978, 1.1.1979,
1.11.1980, 1.1.1981, 1.1.1982 and 1.1.1983.
1985 - 2,000 Pref. shares redeemed. 66,900 No. Equity shares
without payment in cash to the shareholders of Neomer, Ltd.
its merger. 2,000 Pref. shares redeemed.
1989 - A variety of new products were introduced under group Feed
Supplements and Tonics which were well received in the
- The Panpharm Division was started at village Panelav in
Panchmahal district of Gujarat State to undertake manufacture
1990 - A new quinolone antibacterial drug Ciprofloxacin was
in the market.
- The Veterinary Division introduced certain new farm products
ascal, ruman bolus etc. during the year.
- New products such as ginseng preparation and zinc and
complex preparations were introduced in the market.
- 100,000-14% non-convertible debentures were issued. These
debentures are redeemable in three yearly instalments
from 11th May, 1995 with redemption premium of 5% payable
with the last instalment.
1991 - As a result of the research and development activities, the
company developed Roxithronycin, a newer generation bulk
1992 - The veterinary division introduced Cloxacillin Amoxicillin
- Introduction of Cloxacillin Amoxicillin injection in the
1993 - The Expansion of Penicillin capacity to 1000 MMU together
integrated effluent treatment plant was undertaken and series
steps were taken to instal diesel engine driven compressors
constant air supply etc.
- The erstwhile Neomer, Ltd. had a licensed capacity to
6000 mt. polypropylene staple fibre. In addition to this, it
registered with D.G.T.D. for the manufacture of 1000 mt. per
annum. of polypropylene multifilament yarn.
- Under the broad banding policy, Neomer had obtained permission
manufacture other synthetic filament yarn i.e. polyester and
nylon yarn including industrial yarn/tyre cord.
- The company introduced a revolutionary antibiotic
which is used in tissue directed antibiotic therapy.
1995 - With a view to facing this eventuality the company proposed
install gas turbine based captive Co-generations Power Unit at
total outlay of Rs 25 crores.
- Two large pencillin fermentors were installed and
- Algen, Ltd. is a subsidiary of the Company. As at 31st Dec.
10,007 No. of equity shares out of 10,013 No. of equity shares
Rs 10/- each issued by the subsidiary were held by the
- 164,732 No. of equity shares of Rs 100 each at a premium of
850/- per share issued to the shareholders on rights basis.
1996 - 10,00,000 Pref. shares allotted on preferential basis.
1997 - The performance of the pharmaceutical division was affected
Governmental basis imposed on scrip to pencillin
which affected the major brand of the company.
- The Company introduced Nimegesic Gel an important
The Company introduced Rorid liquid for paediatric use,
made suspension of Roxithromycin. The Company
position by the introduction of Clarithro and basic
- The company installed Peniccillin - Gas 600 m.m.u. per
Erythromycin 100 tpa. Also, a second line of extraction
for erythromycin was installed.
- The Alembic Herbals veterinary, a new division of
business was launched in June.
- The Company issued 10,00,000-16% redeemable
cumulative preference shares of Rs 100 each. These are
redeemable at par on 11.2.1999.
- The Company has expanded its reach in the fastest growing
anti-inflammatory segment with the launch of new
molecules Rofecoxib and
2000 - The Company has launched Glycodin Activ Cold & Flu Tablets.
2001 - The Company has launched its version of sildenafil citrate,
under the brand name
`Asigra'. The pill for erectile dysfunction is in two
dosage forms of 25 mg and 50 mg
as against three by most of the other players.
- The Company has launched a new OTC brand, Glycodin Activ
cold and flu tablets.
-Gujarat High court sanctions for the merger of Bulk Drug unit of M/s
Darshak Ltd with the company.
-Enters into an in-licensing pact with Euroresearch for introducing
Gelfix Collagen dressing sponge pads in the country.
-Appoints Mr Nitin Jaywant as the President, Active Pharmaceutical
-Floats a new division called 'SynX' to cater to patients suffering
from condition called Syndrome X .
-Enters into a research pact with Chiron Corporation of US for
-Gets approval from DCGI to manufacture and market Cefetamet Pivoxil
-Ties up with Italian Pharma company, Euroresearch to bring its
products to India.
-Launches 4th generation injectable Cephalosporin Cefepime under the
brand name of Cepime.
-Allots equity shares to the shareholders of M/s Darshak Ltd as per
the scheme of demerger.
-Acquires brand and trade mark rights of obstretical care drug
Yutopar from Solvay Pharmaceuticals BV, Netherlands.
-Launches new division for research and development services, BioArc
-Forays into speciality therapeutics segment.
-Signs agreement with two MNC companies for R & D division.
-Lines up a rights issue of Rs.32.37crs.
-Alembic Limited has informed the Exchange that the company has
despatched the Offer Document and Composite application form to all
the shareholders on December 22, 2003. The Rights Issue is going to
open on December 30, 2003, the last date for receiving requests for
split forms is January 13, 2004 and the Rights Issue will close on
January 28, 2004.
-The comnpany raised Rs 10 crore by placing 90-day commercial paper
(CP) at 4.85 per cent with a mutual fund on March 8th.
-Alembic signs MoU with Xechem International
- Launches a no-calorie sugar substitute, `Zero', on February 2,
-Company has splits its Face value of Shares from Rs 10 to Rs 2
- Alembic Ltd has informed that the Company has acquired API
manufacturing unit of Nirayu Pvt Ltd. situated at Panelav, P.O.
Tajpura, Taluka Halol, Dist. Panchmahals, Gujarat.
-Alembic has recommended dividend at 20%
-Mr. Milin Mehta has been appointed as additional Independent
Director of the company.
-Mr. Ashok Tulankar has been appointed as Vice President - Production
as Additional Director & Whole-Time Director on the Board of the
-Mr. Chandrashekhar P. Buch has been appointed as an Additional -
Non-Executive Independent Director of the Company
-Alembic Ltd has allotted 13,35,15,914 Bonus Shares in the ratio of
-Alembic Ltd has appointed Mr. R. C. Saxena, as Additional
Non-Executive Independent Director.
-The Board has recommended a dividend of Re. 0.20 (10%) per Equity
Share of Rs. 2 each
-Alembic Ltd has recommended a dividend of Re. 0.15/- (7.5%) per
Equity Share of Rs. 2 each.